
ELVN Stock Forecast & Price Target
ELVN Analyst Ratings
Bulls say
Enliven Therapeutics is well-positioned for success with its well-capitalized balance sheet, key development milestones met for ELVN-001, promising results from the ENABLE phase 1b trial, and FDA Fast Track Designation received. With a high likelihood of approval for ELVN-001 in second or later lines of treatment, this clinical-stage biopharmaceutical company is a strong investment opportunity.
Bears say
Enliven Therapeutics is facing several fundamental risks that may affect their financial performance and stock value in the future. These include potential competition from other pharmaceutical companies with similar products, challenges securing regulatory approvals for their main product candidate ELVN-001, potential market access and pricing issues, and potential equity dilution risks. The lack of current revenue and royalty fees also raises concerns about the company's ability to sustain itself in the short term.
This aggregate rating is based on analysts' research of Enliven Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ELVN Analyst Forecast & Price Prediction
Start investing in ELVN
Order type
Buy in
Order amount
Est. shares
0 shares